SEQ-1274 Drug Platform
For ovarian/other cancers
SEQ-1274 and analogs are small molecule inhibitors that are being developed as a potential treatment for patients with ovarian and other cancers.
Our pipeline programs
Advancing a vaccine for the prevention of recurrent UTI, developing anticancer compounds, and compounds against the lung infections of cystic fibrosis patients
At Sequoia Vaccines, Inc., our initial focus is to conduct late state trials for our vaccine for the prevention of recurrent UTI.
| Indication or Program | Preclinical | Phase 1 | Phase 2 | Phase 2/3 | Market |
|---|---|---|---|---|---|
SEQ-400Recurrent Urinary Tract Infections |
Preclinical Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
Phase 2/3 Phase not started
|
Market Phase not started
|
SEQ-1274 drug platformOvarian and Other Cancers |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 2/3 Phase not started
|
Market Phase not started
|
Novel small molecule drug platformCystic Fibrosis Lung Infections |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 2/3 Phase not started
|
Market Phase not started
|
SEQ-400
A vaccine for recurrent urinary tract infections
Our lead program, SEQ-400 is a FimH vaccine that is being developed and evaluated for prevention of recurrent urinary tract infections (UTIs). A Phase 2/3 human study is set to begin in 2023.
About the recurrent UTI programNovel Small Molecule Drug Platform
For lung infections in cystic fibrosis patients
Analogs from a novel small molecule platform are undergoing optimization for inhibition of spreading bacterial biofilms that impact lung physiology of cystic fibrosis patients.
Research & publications
Sequoia’s research and development studies and programs have been published in more than 50 peer-reviewed scientific publications.
View publications